Chinese Market Offers New Life to Many Drugs image

Dow Jones Business News, March 29, 2016
Fanfan Wang, quoting I. Glenn Cohen (Faculty Director)


Read the Full Article

Excerpt from Article:

[...] But the new trend also raises the question of whether China has become a dumping ground for inferior drugs.

I. Glenn Cohen, a Harvard Law School professor who studies medical ethics, said that because of differences in regulatory standards it isn't unusual or unlawful for a company to get a drug approved in one jurisdiction and not another.

For one thing, in China a drug doesn't have to prove superiority over existing drugs--a major hurdle in the U.S., where 90% of candidates get dropped in the clinical-trial process. [...]

fda i. glenn cohen medical tourism pharmaceuticals